Nile Therapeutics
Nile TherapeuticsAbout UsPipelineInvestor RelationsCareersContact
Nile Therapeutics is a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease and other areas of unmet medical need.
In Development
CD-NP
CD-NP is a novel rationally designed chimeric natriuretic peptide in clinical studies for an initial indication of acute decompensated heart failure. » More
2NTX-99
2NTX-99 is a small molecule with anti-atherothrombotic and nitric oxide donating properties that is in pre-clinical development. » More


Recent News
  • October 1, 2008 - Nile Therapeutics to Present at the Maxim Group Growth Conference » Read

  • August 27, 2008 - Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference » Read

  • August 14, 2008 - Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results » Read






Event:Maxim Group Growth Conference
Date:October 7, 2008
Time:9:00am- 9:30am EDT
Location:Presentation: Morosco Room
Breakout session: Plymouth Room
Grand Hyatt Hotel, 109 East 42nd Street, New York, NY 10017
Web Site:http://www.wsw.com/webcast/maxim/nilt.ob



Event:Rodman and Renshaw Annual Global Investment Conference
Date:November 10, 2008
Time:2:00 pm - 2:25pm EDT
Location:Presentation: Kennedy II (4th floor)
The New York Palace Hotel, 455 Madison Avenue (at 50th St.), New York, NY 10022
Web Site:http://www.rodm.com/conferences?id=19



Event:Lazard Capital Markets 5th Annual Healthcare Conference
Date:November 19, 2008
Time:9:00 a.m. (Presentation,) 9:30 a.m. (Breakout Meeting)
Location:The St. Regis, 2 East 55th Street, New York, NY 10022
Web Site:TBA



Email Alerts



Interested investors or potential investors may conveniently receive E-mail alert messages whenever certain new company information is posted to this site. To automatically receive Nile Therapeutics, Inc. e-mail alerts, enter your e-mail address and click on the Subscribe button.